845 studies found for:    pharmacogenomics OR pharmacogenetics
Show Display Options
Rank Status Study
21 Recruiting Utility of PharmacoGenomics for Reducing Adverse Drug Effects
Condition: Genetics of Drug Metabolism
22 Recruiting Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)
Condition: Bipolar Affective Disorder
Intervention: Drug: Mood stabilizer treatment
23 Unknown  Pharmacogenomics Studies of Antidepressants
Conditions: Major Depressive Disorder;   Antidepressive Agents;   Pharmacogenetics;   Venlafaxine;   Fluoxetine
Interventions: Drug: Venlafaxine;   Drug: Fluoxetine
24 Completed Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia
Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
25 Completed Pharmacogenetics of Warfarin in Puerto Ricans.
Conditions: Atrial Fibrillation;   Deep Vein Thrombosis;   Cardiac Valvular Insufficiency;   Antiphospholipid Syndrome;   Coagulopathy
26 Completed Pharmacogenomic of Atazanavir/Efavirenz (ATV/EFV)
Condition: HIV Infections
27 Not yet recruiting Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients
Condition: Anticoagulation
Intervention: Genetic: Pharmacogenetic anticoagulation
28 Recruiting Pharmacogenetic Testing Among Home Health Patients
Conditions: Adverse Drug Events;   Adverse Drug Reactions;   Drug Interaction Potentiation;   Drug Metabolism, Poor, CYP2D6-RELATED;   Drug Metabolism, Poor, CYP2C19-RELATED;   Cytochrome P450 Enzyme Deficiency;   Cytochrome P450 CYP2D6 Enzyme Deficiency;   Cytochrome P450 CYP2C9 Enzyme Deficiency;   Cytochrome P450 CYP2C19 Enzyme Deficiency;   Cytochrome P450 CYP3A Enzyme Deficiency;   Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant;   Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant;   Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Intervention: Genetic: Pharmacogenetic testing
29 Unknown  Pharmacogenomics of Anti-TNF (Anti-tumor Necrosis Factor) Treatment in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
30 Recruiting Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness
Conditions: Depression;   Antidepressant Drug Adverse Reaction
Interventions: Drug: SSRI treated group;   Drug: non-SSRI treated group
31 Withdrawn Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Drug: Cisplatin;   Drug: Cetuximab
32 Completed EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients
Condition: HIV Infection
Intervention: Drug: Efavirenz
33 Completed
Has Results
Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy
Condition: Blood Clotting
Interventions: Genetic: warfarin pharmacogenetic dosing;   Drug: Warfarin
34 Completed Pharmacogenetics of Remifentanil in Patients With Hypertension Undergoing Cesarean Delivery Under General Anesthesia
Conditions: Pregnancy;   Cesarean Delivery;   General Anesthesia
Intervention: Drug: Remifentanil
35 Active, not recruiting Prediction of Antidepressant Response Using Pharmacogenetics and Peripheral Lymphocytic Phenotype
Condition: Depression
Interventions: Drug: responders;   Drug: non-responders
36 Recruiting Pharmacogenomics of New Antiretrovirals
Condition: HIV
37 Completed CYP2D6 Pharmacogenetics in Risperidone-Treated Children
Conditions: Psychiatric Disorders;   Neurodevelopmental Disorders
38 Recruiting Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regiment for Calculating Warfarin Maintenance Dose
Condition: Indications for Warfarin Therapy
Intervention: Drug: Warfarin Sodium
39 Completed
Has Results
First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study
Conditions: Idiopathic Growth Hormone Deficiency;   Turner Syndrome
Intervention: Other: Blood sampling
40 Enrolling by invitation Pharmacogenomics of Thiazolidinediones
Condition: Type 2 Diabetes
Intervention: Drug: Pioglitazone

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years